GlassScriptPhysician profile
Ali Mohammad Alsaadi
NPI 1912941477
$6,402.73
in general payments reported to CMS, 2019-2025
61 companies · $897 in 2025
The $897 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $948 · 2020: $187 · 2021: $1,374 · 2022: $1,209 · 2023: $1,020 · 2024: $768 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,429 · Education: $254 · Travel and Lodging: $2.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,428.57 |
| Education | $253.81 |
| Travel and Lodging | $2.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $573.13 | 2019-2022 | |
| Medtronic, INC. | $378.19 | 2023-2025 | Onyx Frontier, Cardioblate Gemini, Inpen Smart Insulin Delivery System |
| Medtronic Vascular, INC. | $316.06 | 2019 | |
| Glaxosmithkline, LLC. | $282.43 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $260.24 | 2021-2024 | Verquvo |
| Teva Pharmaceuticals USA, INC. | $256.28 | 2020-2023 | Austedo Xr, Ajovy, Austedo |
| Astrazeneca Pharmaceuticals LP | $246.54 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $245.73 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $232.90 | 2019-2021 | |
| Pfizer INC. | $208.31 | 2019-2025 | |
| Exact Sciences Corporation | $206.82 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $191.77 | 2023-2024 | Gemtesa, Aptiom |
| Ucb, INC. | $188.34 | 2021-2024 | Nayzilam |
| Otsuka America Pharmaceutical, INC. | $168.17 | 2021-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $152.28 | 2021-2025 |
Show all 59 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Alsaadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.